MedTrace Logo

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

NCT01937390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 645

Last updated 2018-07-27

Study results available
· View outcomes & findings →

Summary

The objective of the study is to observe the effect of adherence to once-daily administered long-acting bronchodilators (long-acting ß2-agonists \[LABAs\] / long-acting muscarinic antagonists \[LAMAs\]) on patients health related quality of life (HR-QoL) and to assess the relation between symptoms improvement and adherence to Chronic Obstructive Pulmonary Disease (COPD) maintenance therapy

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation

Respimat® inhaler and cartridge Solution for inhalation

DRUG

Indacterol 300 µg

inhalation powder

DRUG

Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule

HandiHaler® device Inhalation powder, hard capsule

DRUG

Indacterol 150 µg

inhalation powder

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-06
Primary Completion
2016-10-22
Completion
2016-10-22

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937390 on ClinicalTrials.gov